Skip to content
CORTCorcept Therapeutics Inc

Earnings

When Corcept Therapeutics Inc reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 23, after the close

Tue, Feb 23, 2027in 97 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 12 – Mar 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$202.13M
Revenue, change from a year earlier: Q3 2026 +64.0%, Q2 2026 +31.7%, Q1 2026 +4.9%, Q4 2025 +11.1%
Net income
$24.29M
Net income, change from a year earlier: Q3 2026 +544.6%, Q2 2026 +22.3%, Q1 2026 n/m, Q4 2025 −21.0%
EPS
—
EPS, change from a year earlier: Q3 2026 +531.3%, Q2 2026 +24.1%, Q1 2026 n/m, Q3 2025 −61.0%

Quarter by quarter

Q3 2026$340.47M+64.0% vs Q3 2025

Latest results

  1. Q3 2026Nov 3, 2026, after the closeThe release3.3%by the close of Nov 4
    Revenue
    $340.47M
    +64.0%
    Net income
    $126.78M
    +544.6%
    EPS
    $1.01
    +531.3%
    Corcept’s third quarter 2026 revenue was $340.5 million, compared to $256.1 million in the second quarter of 2026.
  2. Q2 2026Jul 29, 2026, after the closeThe release+27.3%by the close of Jul 30
    Revenue
    $256.15M
    +31.7%
    Net income
    $42.99M
    +22.3%
    EPS
    $0.36
    +24.1%
  3. Q1 2026Apr 30, 2026, after the closeThe release+10.5%by the close of May 1
    Revenue
    $164.90M
    +4.9%
    Net income
    -$31.76M
    N/M
    EPS
    -$0.30
    N/M
  4. Q4 2025Feb 24, 2026, after the closeThe release0.7%by the close of Feb 25
    Revenue
    $202.13M
    +11.1%
    Net income
    $24.29M
    −21.0%
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · after-hoursNov 3, 202634 d10-Q$340.47M+64.0%$1.013.3%
Q2 2026Jun 30, 2026Jul 29, 2026 · after-hoursJul 29, 202629 d10-Q$256.15M+31.7%$0.36+27.3%
Q1 2026Mar 31, 2026Apr 30, 2026 · after-hoursApr 30, 202630 d10-Q$164.90M+4.9%-$0.30+10.5%
FY 2025
Q4 2025derivedDec 31, 2025Feb 24, 2026 · after-hoursFeb 24, 202655 d10-K$202.13M+11.1%—0.7%
Q3 2025Sep 30, 2025Nov 4, 2025 · after-hoursNov 4, 202535 d10-Q$207.64M+13.7%$0.16+8.0%
Q2 2025Jun 30, 2025Jul 31, 2025 · after-hoursJul 31, 202531 d10-Q$194.43M+18.7%$0.29+2.6%
Q1 2025Mar 31, 2025May 5, 2025 · after-hoursMay 5, 202535 d10-Q$157.21M+7.1%$0.174.5%
FY 2024
Q4 2024derivedDec 31, 2024Feb 26, 2025 · after-hoursFeb 26, 202557 d10-K$181.89M+34.3%—5.6%
Q3 2024Sep 30, 2024Oct 30, 2024 · after-hoursOct 30, 202430 d10-Q$182.55M+47.7%$0.41+4.4%
Q2 2024Jun 30, 2024Jul 29, 2024 · after-hoursJul 29, 202429 d10-Q$163.80M+39.1%$0.32—
Q1 2024Mar 31, 2024May 1, 2024 · after-hoursMay 1, 202431 d10-Q$146.81M+39.0%$0.25+5.1%
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026069501
10-QJul 29, 2026050613
10-QApr 30, 2026028902
10-KFeb 24, 2026011091
10-QNov 4, 2025048841
10-QJul 31, 2025037005
10-QMay 5, 2025022173
10-KFeb 26, 2025008167
10-QOct 30, 2024044322
10-QJul 29, 2024033284

Provenance

ProvenanceData status and checks

Corcept Therapeutics Inc · CIK 1088856 · Engraved from SEC EDGAR